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Abstract
The aim of this study was to examine a possible role for extracellular pyrimidines as inotropic
factors for the heart. First, nucleotide plasma levels were measured to evaluate whether UTP is
released in patients with coronary heart disease. Then, inotropic effects of pyrimidines were
examined in isolated mouse cardiomyocytes. Finally, expression of pyrimidine-selective receptors
(a subgroup of the P2 receptors) was studied in human and mouse heart, using real time
polymerase chain reaction, Western blot, and immunohistochemistry. Venous plasma levels of
UTP were increased (57%) in patients with myocardial infarction. In electrically stimulated
cardiomyocytes the stable P2Y2/4 agonist UTPγS increased contraction by 52%, similar to β1-
adrenergic stimulation with isoproterenol (65%). The P2Y6-agonist UDPγS also increased
cardiomyocyte contraction (35%), an effect abolished by the P2Y6-blocker MRS2578. The
phospholipase C inhibitor U73122 inhibited both the UDPγS and the UTPγS-induced inotropic
effect, indicating an IP3-mediated effect via P2Y6 receptors. The P2Y14 agonist UDP-glucose was
without effect. Quantification of mRNA with real time polymerase chain reaction revealed P2Y2
as the most abundant pyrimidine receptor expressed in cardiomyocytes from man. Presence of
P2Y6 receptor mRNA was detected in both species and confirmed at protein level with Western
blot and immunohistochemistry in man. In conclusion, UTP levels are increased in humans during
myocardial infarction, giving the first evidence for UTP release in man. UTP is a cardiac inotropic
factor most likely by activation of P2Y2 receptors in man. For the first time we demonstrate
inotropic effects of UDP, mediated by P2Y6 receptors via an IP3-dependent pathway. Thus, the
extracellular pyrimidines (UTP and UDP) could be important inotropic factors involved in the
development of cardiac disease.
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The cardiac effects of purines such as adenosine, adenosine triphosphate (ATP), and
adenosine diphosphate (ADP) have been extensively studied since the first functional
findings by Drury and Szent-Györgi in 1929.1 Purines were subsequently found to have
specific receptors in the surface membrane of the cardiac myocytes. However, only a few
studies have focused on the effect of pyrimidines, such as uridine triphosphate (UTP) and
uridine diphosphate (UDP), in the heart.
UTP alone has been shown to have inotropic effects in the heart, but previous studies have
been performed with unstable nonselective agonists, and receptor characterization has not
been possible. Furthermore, even though the release of purines has been extensively studied
in different models, the release of pyrimidines has never been examined in human patients.
The extracellular nucleotides, ATP and ADP, are released from sympathetic nerves,
activated platelets, erythrocytes, cardiac tissue, inflammatory, endothelial, and smooth
muscle cells.4–6 In the heart, hypoxic conditions are prominent activators of ATP release.6, 7
There is limited knowledge considering release of pyrimidines. Continuous release of UDP-
glucose from endothelial cells has been detected, however no correlation to ATP release has
been observed.8 Using a pig model we recently demonstrated that UTP is released from the
heart during ischemia.9 However, the release of pyrimidines from the human heart under
ischemic conditions has not been studied.
The extracellular nucleotides activate membrane-bound purine receptors (P2 receptors),
which is one of the largest known receptor families.10 P2 receptors are divided into two
classes: ligand-gated intrinsic ion channels, called P2X receptors, and G protein– coupled
P2Y receptors.10 New P2Y receptor subtypes activated not only by purines but also
pyrimidines have been identified. UTP, UDP, and UDP glucose activates at least four
subtypes of P2Y receptors: P2Y2, P2Y4, P2Y6, and P2Y14.2, 3 UTP is an agonist for P2Y2 13
and P2Y4 receptors.14 P2Y6 is activated by UDP13, 15 and UTP glucose activates P2Y14
receptors.16 P2Y2 is activated by both UTP and ATP.
The P2Y family is divided into two structurally-distinct subfamilies. The first is composed
of P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors, all coupled to Gq, which promotes
phospholipase C (PLC) and subsequent mobilization of intracellular calcium.11, 12 The
members of the second subfamily P2Y12, P2Y13, and P2Y14 are coupled to Gi, inhibiting
adenylate cyclase.
Extracellular ATP is known to increase cytosolic calcium in cardiac myocytes and to have
inotropic effects.5, 17, 18 We recently examined the effects of purines in cardiomyocytes and
found potent inotropic ATP effects mediated via a P2Y11-like receptor.18 Regarding
pyrimidines, the unstable agonist UTP has been shown to induce a positive inotropic effect
in rat atria and in rat and guinea pig ventricular cardiomyocytes,19–22 but the effects of UDP
and UDP-glucose has not been investigated. Furthermore, there is a need to characterize
which receptor mediates the inotropic effect of UTP.
We wanted to examine whether pyrimidines are released in man, evaluate their inotropic
effects, and investigate which pyrimidine selective receptors are expressed in the human
heart. The first objective was to quantify the plasma level of uridine nucleotides in patients
with acute ischemic heart disease. The second objective was to examine the inotropic effects
of selective pyrimidine receptor agonists. Because of the limited availability of human
cardiomyocytes, pharmacological characterization of pyrimidine selective P2Y receptor
function was done in cardiomyocytes from mice. The third objective was to analyze
expression of P2-receptors in the heart using quantitative real-time polymerase chain
reaction (PCR), Western blot, and immunohistochemistry.
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Patients Enrolled for UTP Measurements
Sixty-four patients were enrolled from the patients admitted for chest pain to the emergency
ward, Lund University Hospital 2001 to 2003. Patients with chest pain within the last hour
before admittance were eligible for inclusion in this study. Exclusion criteria were: patients
treated with aspirin, clopidogrel, dipyridamole, nonsteroidal antiinflammatory drugs,
heparin, low molecular heparin, or warfarin. Even patients who received a bolus dose of
aspirin in the ambulance on their way to hospital were excluded. Furthermore, patients were
excluded if they had a platelet count <140×109/L, hemoglobin <90 g/L, renal failure
(creatinine >140 µmol/L), or hemolysis in blood samples. Based on the diagnosis at
discharge, three prespecified subgroups were compared: chest pain with no sign of cardiac
disease (NCD), non–ST elevation myocardial infarction (NSTEMI), and ST elevation
myocardial infarction (STEMI). The study included 43 men and 21 women in the mean age
of 68±12 years. The NCD group was composed of patients with normal ECGs (or no new
changes compared with a previous ECG), normal values of cardiac markers (TroponinT),
and when appropriate, a negative exercise test. This UTP measurement study was a substudy
of a larger study on ATP release during ischemic heart disease.23 For more methodological
details see below.
Quantification of Nucleotides
UTP was measured in all 64 patients. Based on diagnosis 64 patients were grouped into
STEMI (16 patients), NSTEMI (16 patients), and NCD (32 patients). Sampling was done at
admission. Blood (5 mL) was added to tubes containing citrate and immediately centrifuged
for 10 minutes at 1200g4°C. Platelet contamination was excluded by Bürker chamber
examination. The plasma was aspirated and mixed with an equal amount of 10%
trichloroacetic acid (TCA) to precipitate all proteins and inactivate ectonucleotidases.
Samples were treated and UTP was quantified as previously described.18, 24
Animals
Adult female NMRI mice (B&K AB, Sollentuna, Sweden), 5 to 6 months old, were used for
isolation of cardiomyocytes. The animals were kept in the university animal facilities with
free access to food and water according to regulations of the local animal ethics committee.
Isolation and Contraction of Cardiomyocytes
The mice were euthanized by cervical dislocation. The cardiomyocytes were isolated as
previously described.18
Cardiomyocyte Contraction
The cells could be kept with unaltered contractile properties for up to 4 hours in a Hepes-
buffered saline solution (1.8 mmol/L Ca2+) in room temperature.25 To observe the cell
shortening we used an inverted microscope and a video recording system. The cells were
analyzed in a Krebs-Henseleit solution (1.8 mmol/L Ca2+) composition adjusted to give pH
7.4 when oxygenated with O2/CO2 (95%/5%) at room temperature. Stimulation voltage was
set to 20% above threshold and impulse duration was 4 ms at 0.5Hz. The cell length during
shortening was analyzed using an optical edge tracking method. The shortening, measured
in pixels, was compared before and after addition of drug to the electrically stimulated
cardiomyocyte in the cuvette. The shortening responses were expressed relative to the
amplitude of responses determined in the cells before addition of drug. The extent of
shortening was approximately 5% of total cell length. The cells were stimulated with
additions of the agonists UTPγS or UDPβS. To further investigate the signaling pathway of
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the response to stimulation with UDPβS the contracting cardiomyocytes were incubated
with the P2Y6 blocker MRS2578. The signaling pathway mediating the effect of UDPβS
was also studied by exposure to a PLC inhibitor, U73133, and an adenylyl cyclase inhibitor,
SQ22563. The cells were preincubated for 5 minutes with inhibitors before addition of
agonist.
RT-PCR Assay and Real-Time PCR
Total RNA was prepared from the mouse cardiomyocytes using the RNAeasy column
(Qiagen) and the RNA was reverse-transcribed using Multiscribe RT Kit (Qiagen). Real
time-PCR reactions on mouse RNA were performed with primers designed using the
VectorNTI software (Invitrogen). The transcribed cDNA was amplified in a LightCycler
using 1×LightCycler DNA Master SYBR Green I mix (Roche Diagnostics). The procedure
has previously been described.18 The amount of receptor was expressed relative to the
housekeeping gene GAPDH. To amplify the receptors the following primers were used;
P2Y2 forward (fw) GCTTCAACGAGGACTTCAAG, reversed (rw)
GTAATAAACCAACAGCGGCA P2Y4 fw TCACTTGCCATGACACCTCGG, rw
AATGGTGCGCACAGACTTGC P2Y6: fw TGACCCGTTCCGCTGTGTAC, rw
GCGCTGGAAGCTAATGCAGG, GAPDH fw GGTCATCCCAGAGCTGAACG, rw
TTGCTGTTGAAGTCGCAGGA.
Human Heart Tissue Preparation
Hearts were explanted in the process of heart transplantation from 5 patients who were
between 52 and 64 years of age and experienced ischemic heart disease or dilated
cardiomyopathy. Samples were not taken from infarcted areas. The hearts were immediately
examined in the operating room and myocardial tissue samples from the wall of the left and
right ventricles and the left and right atria were removed gently and immersed in cold
oxygenated Hepes-buffered saline solution. The epicardial and endocardial parts were
removed from the pieces from the ventricles. Tissue samples were snap-frozen in liquid
nitrogen or fixed in formalin immediately after acquisition. Total cellular RNA was
extracted as above. The real-time PCR reactions on human RNA were performed as
described earlier.26
Western Blot
Protein electrophoresis was performed on 10% Tris-HCl polyacrylamide ready gels (Bio-
Rad Laboratories) and electroblotted onto Hybond-C nitrocellulose membranes (0.45 µm;
Amersham Pharmacia Biotech). Protein loading of 15 µg for each well was diluted with
4×SDS-reducing sample buffer. The membranes were incubated with rabbit antihuman
P2Y6 (1:250; GlaxoSmithKline); thereafter, they were incubated with a secondary antibody
(anti-rabbit Ig, horseradish peroxidase-linked, 1:1500; Amersham Life Science). The
proteins were visualized by chemiluminescence using the ECLTM Western blotting RPN
2108 system (Amersham Pharmacia Biotech).
Immunocytochemistry
Human heart tissue samples were fixed in formalin, embedded in paraffin, and cut in 5-µm
sections. The avidin-biotin-peroxidase complex method for antibody detection was used.
After incubation with normal serum, sections were incubated with anti-P2Y6 antibodies.
Anti-P2Y6 antibody was produced by GlaxoSmithKline. Bound primary antibody was
detected using VECTASTAIN Elite ABC kit and developed with DAB substrate kit for
peroxidase. After counter-staining with VECTOR hematoxylin QS nuclear counterstain
(Modified Mayer Formula), the slides were examined microscopically.
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Isoproterenol, SQ22563, and U73122 were purchased from Sigma. UTPγS and UDPγS
were gifts from Inspire Pharmaceuticals (Chapel Hill, NC); MRS2578 was a gift from KA
Jacobson (National Institutes of Health, Bethesda, Md). All the drugs were dissolved in
0.9% saline.
Ethics
The Ethics Committee of Lund University approved the project involving human subjects.
The project complies with the Declaration of Helsinki and all patients gave written consent
to participation in the study. The animal study conforms to the Guide for the Care and Use
of Laboratory Animals published by the National Institutes of Health (NIH Publication No.
85-23, revised 1996). The animal experiments were approved by the local animal ethics
committee.
Calculation and Statistics
Calculations and statistics were performed using the Graph-Pad Prism 3.02 software. n
denotes the number of cells if otherwise not stated. Statistical significance was accepted
when P<0.05. Raw data from cardiomyocyte experiments were analyzed with paired Student
t test, and cardiomyocyte shortening after drug addition was compared with cardiomyocyte
shortening before addition of the drug, referred to as the control. Values are presented as
mean±SEM. UTP levels were compared with Kruskal–Wallis test followed by Dunnett
multiple comparisons. Spearman rank correlation coefficient test was used for regression
analysis.
Results
Human venous plasma levels of UTP were significantly increased in STEMI (22±3, n=17
nmol/L, P<0.05) compared with NCD (14±3nmol/L, n=32) (Figure 1a). There was no
difference between patients with NSTEMI compared with controls (NCD). There was no
difference between patients with diabetes mellitus or on aspirin treatment compared with
controls. No difference in nucleotide concentration was found between males and females.
Regression analysis of the whole material revealed a correlation between UTP and ATP
(r2=0.44, P<0.001). UTP was present at ≈10% of the ATP concentration (Figure 1b).
Effects of β-adrenergic and uridine nucleotide stimulation on shortening responses of mouse
cardiomyocytes are shown in Figure 2. Isoproterenol (1 µmol/L) caused a 65±17% (n=24)
increase in the cardiomyocyte contraction. The P2Y2/4 receptor agonist UTPγS (1 µmol/L)
caused an increase of 52±20% (n=20; Figure 2). The specific P2Y6 receptor agonist UDPγS
(1 µmol/L) caused a 37±15% (n=19) increase in the myocyte contraction (Figure 2). The
specific P2Y14 receptor agonist UDP glucose had no inotropic effects (Figure 2). The
inotropic response to UDPβS was abolished by the selective P2Y6 blocker MRS2578 (10
µmol/L) and by the PLC inhibitor U73122 (10 µmol/L) (Figure 3). The UTPγS-induced
response was unaffected by the presence of the adenylyl cyclase inhibitor, SQ22563, but the
effect was inhibited by U73122 (Figure 3). No effects were observed on cardiomyocyte
shortening when MRS2578, U73122, and SQ22563 were administered separately (data not
shown). Absolute values of cell contractions were (% cell shortening of total cell length):
control (5.0±0.4%), isoproterenol (8.8±1.2%), UTPγS (8.1±1.4%), UDPβS (7.7±0.8),
U73122 (5.2±0.8%), UDPβS+U73122 (4.4±0.8%), and SQ22563 (5.1±0.6%); data
presented as mean±SEM.
The expression of P2 receptor mRNA in mouse cardiomyocytes was quantified using real-
time PCR. P2Y2 and P2Y4 were the most abundant pyrimidine selective receptors (P2Y4
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133±19% expressed as percent of P2Y2 receptor mRNA) whereas expression of the P2Y6
receptor mRNA was lower (25±5%). The ADP responsive P2Y1 receptor had the highest
expression among the P2Y receptors in the mouse heart. The results are shown in Figure 4.
The expression of P2 receptor mRNA was also quantified in the human heart (Figure 5). In
the left ventricle P2Y2 was by far the highest expressed receptor followed by P2Y1 (52±11%
expressed as percent of P2Y2 receptor mRNA). P2Y6 (8.2±0.3%) and P2Y11 (l7±2%) were
also present in significant amounts, but the P2Y4 receptor had very low expression. The
expression pattern was similar in the right ventricle and in the atria.
P2Y6 was detected using specific antibodies in immunohistochemistry and Western blot.
The receptor was detected in both ventricles and atria of the human heart with a band of
approximately 45 kD, which is in agreement with the expected size (Figure 6a). No band
was found in the control membrane, indicating that the band represents the P2Y6 receptor.
The same antibody was used in immunohistochemistry of human left ventricular heart tissue
obtained from the explant heart at transplantation. Positive staining was seen for P2Y6 that
was absent when control peptide was added or in controls without the primary antibody
(Figure 6b). P2Y6 expression was only seen in cardiomyocytes and not in interstitial cells.
The P2Y6 receptor expression was seen in the whole cardiomyocyte, with increased
expression at the intercalated discs.
Discussion
In our study we demonstrate that the plasma levels of UTP are significantly elevated in
patients with acute myocardial infarction. A combination of pharmacology and mRNA
quantification indicates that UTP is probably acting via P2Y2 receptors in man, and via both
P2Y2 and P2Y4 receptors on cardiomyocytes from mice. Our results indicate that UDP is a
novel inotropic factor acting via P2Y6 receptors. The first demonstration of UTP release
used [3H]uridinelabeled endothelial cells. In the study, [3H]UTP release occurred in
response to increased flow.27 Since the development of the first sensitive quantitative assay
for UTP, its release has been measured from a variety of cells including platelets,
leukocytes, primary airway epithelial cells, rat astrocytes, and several other cell lines.24 To
our knowledge, we are now the first to quantify UTP levels in human plasma. UTP levels
correlated significantly with ATP, indicating corelease of the nucleotides. The UTP levels
were ≈1:10 of the ATP levels, which is in the vicinity of the relationship between UTP and
ATP in most cell types (usually approximately 1:5).24 Patients with acute myocardial
infarction had significantly higher UTP levels, indicating release during ischemia. It was
only possible to measure UTP from venous samples and thus it is not possible to establish
the source of the released UTP. However, we recently performed animal studies in which
the release was measured in blood from the cardiac vein, demonstrating UTP release from
the heart during cardiac ischemia.9 UTP is therefore likely to be released from the heart by
cardiomyocytes, but endothelial and red blood cells may also contribute. Platelets are less
likely as a source because they contain minor amounts of UTP.24
On the surface of cardiac cells there are ectonucleotidases rapidly hydrolyzing nucleotides
(UTP to UDP to UMP to uridine).28 Because UTP is rapidly degraded to UDP, these
findings of cardiac UTP release indicate that UDP will be present in the circulation with
possible actions on the heart via P2Y6 receptors. This rapid degradation also results in much
lower plasma levels than the actual nucleotide concentrations at the cell surface. Measuring
UTP release from the heart during cardiac ischemia the nucleotide concentrations in plasma
are in 10−7 mol/L range.9 In this experiment we therefore choose the concentration of 10−6
mol/L, that may represent a physiologically relevant concentration.
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Extracellular pyrimidines have several effects in the cardiovascular system. In the
vasculature UDP and UTP induce vasoconstriction through P2Y receptor stimulation on
vascular smooth muscle cells, but also dilatation acting on P2Y receptors on endothelial
cells, thereby regulating vascular tone and blood pressure.3, 4, 29–31 Extracellular UTP and
UDP have also been shown to mediate growth stimulation and cell migration in vascular
smooth muscle cells and intimal hyperplasia.32–35 In rat cardiomyocytes, UTP has also been
shown to cause hypertrophic growth.36 Furthermore, UTP is known to be a positive
inotropic agent in rat atria and rat and guinea pig ventricular cardiomyocytes.19–22
UTP is selective to P2Y2/4 and UDP to P2Y6 in both man and mouse. Earlier studies have
been performed with rapidly degradable UTP, making receptor characterization difficult.
UTP is degraded to UDP and may even transfer phosphate groups to generate ATP.
Experience from blood vessels and other tissues have shown that it is necessary to use stable
and selective compounds.37 To analyze the inotropic effect of pyrimidine selective receptors
stimulation, without interfering with degradation products, we used the stable pyrimidines:
UTPγS for selective stimulation of P2Y2 and P2Y4 receptors and UDPβS to selectively
stimulate the P2Y6 receptor.35, 37 UDP-glucose occurs naturally but is resistant to
degradation and selective for P2Y14 receptors.
In the present study UTPγS was nearly as strong an inotropic stimulator as the same
concentration of isoproterenol. The selectivity of UTPγS firmly establishes that the effect is
mediated via P2Y2 or P2Y4 receptors. UDPβS also induced a positive inotropic effect in the
cardiomyocytes, although slightly weaker. Recently, a selective P2Y6 receptor blocker,
MRS2578, was developed by Jacobson and coworkers. 38 Using this novel antagonist, the
UDPβS response was totally blocked. This strongly indicates that UDP is a positive
inotropic factor acting on the P2Y6 receptor. The P2Y14 receptor is coupled to Gi, which
inhibits adenylyl cyclase resulting in a decreased cAMP level. This would theoretically
result in a negative inotropic effect, but no inhibitory or stimulatory effect was observed
when exposing the cardiomyocytes to UDP-glucose.
The inotropic mechanisms were studied using selective inhibitors of the intracellular
pathways. The receptors P2Y2, P2Y4, and P2Y6 are Gq-coupled receptors mediating their
response via PLC, resulting in increased IP3 and increased intracellular Ca2+ levels. UTP
has previously been shown to be a positive inotropic agent in the heart mediating its effect
via a PLC pathway.19 There is also some evidence that UTP induce cAMP elevation.39 The
inotropic response induced by UTP was confirmed using the stable analogue, UTPγS,
confirming activation of the receptors P2Y2 or P2Y4. The PLC dependent pathway of
P2Y2/4 was confirmed by the decreased inotropic effect of UTPγS in presence of U73122.
The possible involvement of cAMP was excluded because the adenylyl cyclase inhibitor
SQ22563 did not attenuate the response to UTPγS. The response to UDPβS was blocked by
the PLC inhibitor U73122, confirming the involvement of a Gq-coupled receptor acting via
IP3 generation.
To help discriminating between P2Y2 and P2Y4 effects and to establish cardiac expression
patterns in man, we used real-time PCR to quantify the mRNA expression of P2 receptors in
heart tissue from man and mouse. The P2Y2 receptor was abundant in both human and
mouse heart tissue. The P2Y4 receptor was absent in man whereas in mouse it was present to
about the same extent as P2Y2. This is similar to heart tissue from rat where P2Y2 and P2Y4
have shown to be expressed to the same extent.40 mRNA for the P2Y6 receptor was present
in both mouse and man, but at a relatively low level. It is well known that the mRNA
expression may not correlate directly with functional importance. Furthermore, the P2Y6
receptor has previously been shown to be more potently activated in vascular smooth
muscles compared with the P2Y2 receptor, even though the receptors were expressed to
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about the similar extent at the mRNA level.26, 30, 40 This is probably because the P2Y6
receptor is resistant to desensitization during continued agonist stimulation.41, 42 Detecting
P2Y6 in human tissue by immunohistochemistry verified expression on the protein level and
the functional pharmacology clearly demonstrated P2Y6 receptor mediated effects.
Apart from the pyrimidine selective receptors we also detected the ATP receptor P2Y11 in
the human heart. This is consistent with recent published functional data from mouse
cardiomyocytes.18 The murine P2Y11 receptor is not yet cloned, preventing quantification of
its mRNA in mouse. P2Y1 was abundantly expressed in both species. However, previous
functional studies of this receptor have not revealed any inotropic function in mouse
cardiomyocytes.18
The presence of pyrimidines in the circulation and receptors by which UTP and UDP can
activate IP3 in cardiomyocytes stimulating both inotropy and hypertrophy could indicate a
similar role for pyrimidines as for angiotensin II. Angiotensin II receptor antagonists and
angiotensin converting enzyme (ACE) inhibitors have been clinically successful in the
treatment of hypertension and heart failure. Similar beneficial effects could possibly be
found for selective UTP and UDP receptor antagonists, inhibiting peripheral resistance,
inotropy, and cardiac hypertrophy. Another interesting aspect is protection during hypoxia.
Yitzhaki and coworkers recently found that UTP protects rat cardiomyocytes against
hypoxic injury.43 Together with our recent finding of UTP release during preconditioning9 it
suggests that UTP could be involved in the preconditioning mechanism, ie, partly explaining
why a brief period of ischemia protects against a subsequent period of hypoxia. Our receptor
quantification in the human heart suggests that it is the P2Y2 receptor that is the appropriate
target for drug therapy aiming at cardiac protection during myocardial infarction. The
parallel release of UTP together with ATP could be important both by providing additional
inotropic pathways but also by having other effects on the cardiomyocyte such as
hypertrophic growth or protection against hypoxic stress. Furthermore, ATP effects are often
counteracted by its degradation product adenosine. This is not the case for UTP.
In conclusion, patients with myocardial infarction have higher plasma levels of UTP. UTP
and UDP induce a pronounced inotropic effect on mouse cardiomyocytes. mRNA
quantification indicates that the inotropic effects of UTP are mediated via P2Y2 and/or P2Y4
receptors in mice and probably mediated by P2Y2 in man. We provide novel evidence for
inotropic effects of UDP acting on the P2Y6 receptor on mouse cardiomyocytes. The
mechanisms are mediated via PLC-mediated signaling and independent of cAMP. The
extracellular pyrimidines UTP and UDP may be inotropic factors in man acting on P2Y2 and
P2Y6 receptors. Synthetic agonists could thus be used as inotropic agents during circulatory
shock, and antagonists may have effects similar to angiotensin II receptor blockers being
beneficial in the treatment of hypertension and congestive heart failure.
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a, Plasma levels of UTP in humans. Plasma concentrations of UTP in NCD (no sign of
cardiac disease) (n=32), NSTEMI (non–ST elevation myocardial infarction, n=16), and
STEMI (ST elevation myocardial infarction, n=16) groups expressed as mean values±SEM.
*P<0.05, compared with NCD. b, Correlation between plasma concentrations of UTP and
ATP in human blood from controls and patients with acute myocardial infarction. The UTP
levels were ≈1:10 of the ATP levels. n=64 patients.
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Effects of β1 agonist (isoproterenol) and stable UTP and UDP analogs on cardiomyocyte
cell shortening. UTPγS (1 µmol/L) and UDPβS (1 µmol/L) induced positive inotropic
effects. Contraction to isoproterenol (1 µmol/L) is shown as a control for inotropic effects.
UDP glucose did not have any effect. The contractions are expressed as the cardiomyocyte
shortening in percent of the control (contracting cardiomyocyte without drug addition). Data
are shown as means±SEM, n=19 to 24 cells from 3 to 5 mice.
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Effects on the pyrimidine-induced cardiomyocyte shortening by selective inhibitors. The
response to UDPβS (1 µmol/L, data also shown in Figure 2) was inhibited by the P2Y6
antagonist MRS2573 (10 µmol/L), and the response to UDPβS (1 µmol/L) was inhibited by
the PLC inhibitor U73122 (10 µmol/L). The response to UTPγS (1 µmol/L, data also shown
in Figure 2) was not affected by the adenylyl cyclase inhibitor SQ22563. The contractions
are expressed as the cardiomyocyte shortening in percent of the control. Data are shown as
mean±SEM, n=6 to 19 cells from 3 mice.
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The mRNA expression of P2 receptors in mouse cardiomyocytes analyzed with real-time
PCR. Expression of P2Y1, P2Y2, P2Y4, and P2Y6 were detected. GAPDH was used as
reference gene, and P2Y2 was chosen to be the calibrator. n=5 mice.
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Quantification of P2Y receptor mRNA in left and right ventricles (LV and RV) and atria
(LA and RA) of human hearts analyzed with real-time PCR. Expression of P2Y1, P2Y2,
P2Y6, and P2Y11 were detected. P2Y2 was most abundant. Similar patterns were observed
in right ventricle and both atria. Tissue from 5 patients was analyzed.
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P2Y6 was detected using specific antibodies in immunohistochemistry and Western blot. a,
Western blot on P2Y6 in left and right ventricles (LV and RV) and atria (LA and RA) of
human heart. The receptor was detected in both ventricles and atria of the human heart with
a band of approximately 45 kD, which is in agreement with the expected size. No band was
found in the control membrane, indicating that the band represents the P2Y6 receptor. b, The
same antibody was used in immunohistochemistry of human left ventricular heart tissue
obtained from the explant heart at transplantation. Positive immunoreactive staining (brown)
was seen for P2Y6 (left) that was absent when control peptide was added or in controls
without the primary peptide (right).
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